Adult Congenital Heart Disease in the 21st Century 2018

Adult Congenital Heart Disease in the 21st Century 2018 Banner

Date & Location
Friday, April 13, 2018, 7:00 AM - Saturday, April 14, 2018, 6:00 PM, Hyattsville, MD

Target Audience
Cardiology, Cardiovascular Surgery, Critical Care, Emergency Medicine, Family Medicine, Obstetrics/Gynecology, Pediatrics


Online registration is now closed. 

If you have a question about your registration, please call us at (202) 780-1655 before 12:00 pm on Thursday April 12, 2018. After 2pm on Thursday, April 12, 2018, you will need to register on-site. 

On-site registration will open at the College Park Marriott Hotel and Conference Center, Hyattsville, MD on Friday April 13, at 7 AM. 

Due to advances in medical and surgical therapies for patients with congenital heart disease (CHD), children and adolescents with CHD have over a 90% surgical rate.  As a result, the number of adults with CHD in the United States has now surpassed the number of children with these conditions.  This includes not only patients with simple CHD but also those with complex CHD.  By 2010, adult CHD patients accounted for 2/3 of patients with severe and other forms of CHD.  It is estimated that there are currently over 1.3 million adults alive with CHD in the United States.  This number is expected to increase by 5% annually.  As this population increases, it is important for them to remain in care as loss to follow-up results in increasing healthcare costs and increased morbidity.

Innovations and new technologies for diagnosis, evaluation, and treatment are continually being developed for patients with CHD and improved survival has largely been due to advancement of medical/surgical therapies.  Novel approaches to transcatheter (stent/valve) interventions, ventricular assist devices, 3D printing of complex cardiac anatomy, pacemaker therapies, and advanced MRI imaging are being developed and utilized at rapid rates.  In addition, understanding and exploring the applicability of emerging heart failure and pulmonary hypertension therapies in CHD patients will provide new treatment options for this unique population.  Understanding these new therapies is critical to ensure that patients continue to receive the best care aimed not only at reducing mortality but also at reducing morbidities. 

CHD represents a medical challenge throughout a patient’s lifespan including managing pregnancies in an increasing number of women with CHD who are in their childbearing years.  Women with CHD are 8 times as likely to experience cardiovascular complications during pregnancy and have a 6 times higher likelihood of dying compared to women without CHD.  Women with complex congenital heart disease are twice as likely to have cardiovascular complications compared to those with simple heart defects.  Managing these patients through a multidisciplinary approach and understanding how to develop these programs are critical to the health of both mother and child.

Patients with CHD are also encountering an increasing number of non-cardiac co-morbidities including kidney, liver, lung, and mental health issues.  In addition, there has been growing evidence on the neurocognitive challenges CHD patients face in childhood and adulthood.  This impacts every aspect of a patient’s life including school performance, eventual employment opportunities, and performing complex tasks such as managing one’s own healthcare.  As patients continue to grow older, understanding how to screen and manage these co-morbidities will be important for maintaining their overall health and improving their quality of life.  Further understanding how to manage the neurocognitive challenges CHD patients face will ultimately enable patients to better manage their complex healthcare needs.

It is important to recognize that CHD patients and their families are important partners in managing their healthcare. This two day conference will not only focus on complex medical conditions and novel medical therapies but the second day will be a combined conference with CHD patients, families, and healthcare providers.  Exploring novel utilities of therapies including transcatheter valve placement, ventricular assist devices, pulmonary hypertension medications, pacemaker innovations, non-pharmacological mental health  therapies and MRI guided therapies will be a focus throughout the meeting,  In addition, several challenging aspects of CHD including the management of coarctation of the aorta, the diagnosis and management of non-cardiac complications, and the incidence and consequences of neurodevelopmental challenges will also be discussed.  The second day of the meeting will continue to provide healthcare providers with pertinent information on diagnosis and treatment but will also offer numerous sessions to patients, including several workshops focused on building key skills needed to manage CHD throughout the lifespan.  By interacting with CHD patients and families, this conference offers healthcare providers a unique perspective on CHD management including the importance of partnering with the patients and their families.  We are pleased to present this conference with the endorsement of the Adult Congenital Heart Association and Mended Little Hearts.

Target Audience

This conference is intended for pediatricians, primary care physicians, internists, cardiologists and surgeons who specialize in both pediatric and adult CHD, as well as maternal-fetal medicine specialists, obstetricians and gynecologists, electrophysiologists, anesthesiologists, radiologists residents, fellows, physician assistants, nurse practitioners, nurses, geneticists and other members of the healthcare team interested in the evaluation, diagnosis and management of adults with congenital heart disease.


After completing this activity, the participant will be able to;
  1. Identify the increasing prevalence of adults with congenital heart disease and address some of the complications that can result from lifelong congenital heart disease.
  2. Consult and coordinate with expert maternal/fetal medicine care for optimization of outcomes for mothers and babies
  3. Appraise the catheter-based interventional procedures in adults with congenital heart disease, and compare the risks and benefits of each modality and approach.
  4. Identify the prevalence of mood disorders in adult congenital heart disease patients.
  5. Identify how to evaluate and treat patients with coarctation of the aorta.
  6. Review new and innovative therapies that might be utilized for patients with adult congenital heart disease.
  7. Identify and understand the implications of neurocognitive challenges that adults with congenital heart disease experience.
  8. Recognize the extra-cardiac complications that occur in adults with congenital heart disease.
  9. Consult and coordinate with ACHD experts for cardiac transplantation and advanced mechanical support evaluation in ACHD patients.
  10. Recognize the importance of consulting ACHD specialists in the evaluation and care of ACHD patients with pulmonary hypertension.

  • Physician: $275
  • Resident/Fellow: $175
  • Advanced Practice Clinicians: $175
  • Nurse: $175
  • Allied Health Professional: $175
  • Industry: $300

FRIDAY ONLY (April 13)

  • Physician: $195
  • Resident/Fellow: $125
  • Advanced Practice Clinicians: $125
  • Nurse: $125
  • Allied Health Professional: $125
  • Industry: $300

**If you are a patient or family member, please navigate to the website to register for the conference.**

Cancellation Policy

Cancellations made in writing by March 1, 2018 will be subject to a 50% penalty. No refunds will be given after  March 1, 2018 Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee, but is not responsible for any travel costs.  Please note registration fees are non-transferable.

Please call 202-780-1655. or email if you have any questions or need any additional information.


In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 12.75 Interprofessional Continuing Education (IPCE) credits for learning and change.